Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study

• Published in: Osteoporosis international Vol. 14; no. 10; pp. 801 - 807
• Main Authors: RINGE, J. D, DORST, A, FABER, H, IBACH, K, SORENSON, F
• Format: Journal Article
• Language: English
• Published: London Springer 01.10.2003; Springer Nature B.V
• Subjects: Aged; Back Pain - prevention & control; Biological and medical sciences; Body Height - drug effects; Bone Density - drug effects; Diphosphonates - adverse effects; Diphosphonates - therapeutic use; Drug Administration Schedule; Drug toxicity and drugs side effects treatment; Female; Glucocorticoids - adverse effects; Humans; Hydroxycholecalciferols - therapeutic use; Injections, Intravenous; Male; Medical sciences; Middle Aged; Osteoporosis - chemically induced; Osteoporosis - complications; Osteoporosis - physiopathology; Pharmacology. Drug treatments; Spinal Fractures - etiology; Spinal Fractures - prevention & control; Toxicity: osteoarticular system; Human; Corticosteroid; Intravenous administration; Toxicity; Treatment efficiency; Diseases of the osteoarticular system; Diphosphonic acid derivatives; Ibandronic acid; Vertebra; Bone disease; Fracture; Spine disease; Bisphosphonates; Trauma; Long term; Prevention; Osteoporosis; Chemotherapy; Treatment; Risk factor; Bone

Despite its well-known benefits, chronic corticosteroid therapy causes osteoporotic fractures in approximately 30-50% of patients treated. To prevent the occurrence of these fractures, treatment with oral bisphosphonates is recommended. However, current oral bisphosphonates, which are given either d...